Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Adaptimmune Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Adaptimmune Therapeutics şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.9%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$0.28
Temettü verim tahmini	n/a

Son temettü güncellemeleri

Güncelleme yok

Recent updates

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Sep 26

Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Apr 16

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Feb 22

Adaptimmune: Drug Approval Now Imminent?

Feb 02

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Dec 27

News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

Nov 09

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Mar 08

Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

Feb 20

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Nov 09

Adaptimmune Therapeutics: Depressed Despite Upcoming BLA

Sep 20

We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Sep 15

Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Aug 10

Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics

Aug 03

Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

Jun 29

Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA

Jun 19

Adaptimmune Therapeutics: A Little More Patience May Be Profitable

Mar 06

Circling Back On Adaptimmune Therapeutics

Dec 15

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Dec 02

Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming

Sep 29

We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate

Aug 14

Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches

Jul 29

Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts

Jun 16

Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow

Jun 05

Adaptimmune slips as Barclays initiates with an underweight rating

May 28

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: ADAP şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: ADAP şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Adaptimmune Therapeutics Piyasaya Karşı Temettü Getirisi

ADAP temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (ADAP)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Biotechs)	1.9%
Analist tahmini (ADAP) (3 yıla kadar)	n/a

Önemli Temettü: ADAP şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, ADAP şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: ADAP şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: ADAP herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Adaptimmune Therapeutics Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%

Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions

Consensus revenue estimates increase by 152%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Adaptimmune Therapeutics plc to Report Q2, 2024 Results on Aug 12, 2024

Consensus revenue estimates increase by 25%

Adaptimmune Therapeutics plc Receives U.S. FDA Accelerated Approval of TECELRA®

Price target increased by 9.6% to US$2.74

Consensus EPS estimates upgraded to US$0.44 loss

Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024

Consensus EPS estimates fall by 19%

Consensus revenue estimates decrease by 59%, EPS upgraded

New major risk - Revenue and earnings growth

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Financial position

Consensus EPS estimates upgraded to US$0.25 loss, revenue downgraded

Adaptimmune Therapeutics plc to Report Q1, 2024 Results on May 15, 2024

Price target decreased by 7.1% to US$3.50

Adaptimmune: Huge Opportunity Amid Their Setback With Genentech

Consensus EPS estimates fall by 11%

Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet

Consensus estimates of losses per share improve by 21%

Adaptimmune Therapeutics plc, Annual General Meeting, May 14, 2024

New major risk - Shareholder dilution

Consensus revenue estimates increase by 56%

New major risk - Financial position

Adaptimmune Therapeutics plc Appoints Cintia Piccina as Chief Commercial Officer, Effective March 18, 2024

New major risk - Share price stability

Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Adaptimmune Therapeutics plc to Report Q4, 2023 Results on Mar 06, 2024

Adaptimmune Therapeutics Regains Nasdaq Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5450(a)(1)

Adaptimmune: Drug Approval Now Imminent?

Adaptimmune Therapeutics plc Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review

Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Adaptimmune Therapeutics plc Completes Submission of Rolling Biologics License Application to U.S. FDA for Afami-Cel for the Treatment of Advanced Synovial Sarcoma

Consensus estimates of losses per share improve by 26%

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts

Adaptimmune Therapeutics plc to Report Q3, 2023 Results on Nov 08, 2023

Adaptimmune Therapeutics Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement of its American Depositary Shares

Price target decreased by 24% to US$3.77

Consensus EPS estimates upgraded to US$0.45 loss, revenue downgraded

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Adaptimmune Therapeutics plc to Report Q2, 2023 Results on Aug 09, 2023

Adaptimmune Therapeutics plc (NasdaqGS:ADAP) completed the acquisition of TCR2 Therapeutics Inc. (NasdaqGS:TCRR) from a group of shareholders.

First quarter 2023 earnings released: EPS: US$0.006 (vs US$0.32 loss in 1Q 2022)

Price target decreased by 7.1% to US$5.58

Consensus revenue estimates increase by 65%

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans

Adaptimmune Therapeutics plc Announces Management Changes

Insufficient new directors

Price target increased to US$5.40

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)

Adaptimmune Therapeutics plc to Report Q3, 2022 Results on Nov 08, 2022

Price target decreased to US$4.90

Adaptimmune Therapeutics: Depressed Despite Upcoming BLA

We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow

Consensus forecasts updated

Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022

Second quarter 2022 earnings released: US$0.28 loss per share (vs US$0.25 loss in 2Q 2021)

Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics

Adaptimmune Therapeutics plc to Report Q2, 2022 Results on Aug 04, 2022

Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022

Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA

Price target decreased to US$5.80

Insufficient new directors

Adaptimmune Therapeutics plc Present Preclinical Proof-Of-Concept Data from Its Second Next-Generation SPEAR T-cell

Adaptimmune Therapeutics plc Appoints Joanna Brewer as Chief Scientific Officer

Adaptimmune Therapeutics plc, Annual General Meeting, May 25, 2022

Adaptimmune Therapeutics plc Presents MAGE-A4 Expression Data from Its Screening Protocol At American Association for Cancer Research

Adaptimmune Therapeutics: A Little More Patience May Be Profitable